Noile-Immune Biotech Inc. (TYO:4893)
Japan · Delayed Price · Currency is JPY 87.00
-1.00 (-1.14%)
Oct 26, 2026, 3:30 PM JST
Noile-Immune Biotech Revenue
Noile-Immune Biotech had revenue of 1.00M JPY in the twelve months ending June 30, 2026, down -88.89% year-over-year. In the year 2025, Noile-Immune Biotech had annual revenue of 5.00M, down -28.57%. That makes Noile-Immune Biotech the 47,408th largest company in the world by revenue and 3,876th in Japan.
Revenue (ttm)
1.00M
Revenue Growth
-88.89%
P/S Ratio
3,775.72
Revenue / Employee
43.48K
Employees
23
Market Cap
3.78B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.00M | -2.00M | -28.57% |
| Dec 31, 2024 | 7.00M | -309.00M | -97.78% |
| Dec 31, 2023 | 316.00M | -309.00M | -49.44% |
| Dec 31, 2022 | 625.00M | 525.00M | 525.00% |
| Dec 31, 2021 | 100.00M | 3.00M | 3.09% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Transgenic Group | 13.64B |
| Kohjin Bio | 4.69B |
| Human Metabolome Technologies | 1.42B |
| PRISM BioLab Co.,LTD | 737.27M |
| Kringle Pharma | 342.21M |
| Cyfuse Biomedical K.K. | 305.00M |
| D. Western Therapeutics Institute | 247.00M |
| Ribomic | 7.50M |